Ocugen Inc (OCGN) - Total Liabilities
Based on the latest financial reports, Ocugen Inc (OCGN) has total liabilities worth $54.06 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore OCGN operating cash flow to assess how effectively this company generates cash.
Ocugen Inc - Total Liabilities Trend (2012–2024)
This chart illustrates how Ocugen Inc's total liabilities have evolved over time, based on quarterly financial data. Check OCGN financial resilience to evaluate the company's liquid asset resilience ratio.
Ocugen Inc Competitors by Total Liabilities
The table below lists competitors of Ocugen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gemtek Technology Co Ltd
TW:4906
|
Taiwan | NT$5.74 Billion |
|
Top Gum Industries Ltd
TA:TPGM
|
Israel | ILA85.07 Million |
|
Magnum Bhd
KLSE:3859
|
Malaysia | RM1.02 Billion |
|
Sygnity SA
WAR:SGN
|
Poland | zł104.72 Million |
|
Jiang Su New Technology Co. Ltd.
SHE:301229
|
China | CN¥761.38 Million |
|
Cosmo Chem
KO:005420
|
Korea | ₩604.63 Billion |
|
Banco de Valores SA
BA:VALO
|
Argentina | AR$2.14 Trillion |
|
Shaanxi Jinye Science Technology and Education Group Co Ltd
SHE:000812
|
China | CN¥3.90 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Ocugen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Ocugen Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 15.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.94 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ocugen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ocugen Inc (2012–2024)
The table below shows the annual total liabilities of Ocugen Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $52.81 Million | +120.20% |
| 2023-12-31 | $23.98 Million | -30.79% |
| 2022-12-31 | $34.65 Million | +248.50% |
| 2021-12-31 | $9.94 Million | +70.67% |
| 2020-12-31 | $5.83 Million | +0.64% |
| 2019-12-31 | $5.79 Million | -67.63% |
| 2018-12-31 | $17.89 Million | -19.80% |
| 2017-12-31 | $22.30 Million | -0.92% |
| 2016-12-31 | $22.51 Million | +162.12% |
| 2015-12-31 | $8.59 Million | -23.95% |
| 2014-12-31 | $11.29 Million | -87.50% |
| 2013-12-31 | $90.35 Million | +121.69% |
| 2012-12-31 | $40.76 Million | -- |
About Ocugen Inc
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase… Read more